# Evaluation of Ocoxin®-Viusid® in Breast Cancer

> **NCT03576521** · PHASE2 · COMPLETED · sponsor: **Catalysis SL** · enrollment: 120 (actual)

## Conditions studied

- Breast Cancer
- Breast Carcinoma
- Adriamycin Toxicity
- Cyclosporine Toxicity

## Interventions

- **COMBINATION_PRODUCT:** CT + Ocoxin-Viusid
- **COMBINATION_PRODUCT:** CT + Placebo

## Key facts

- **NCT ID:** NCT03576521
- **Lead sponsor:** Catalysis SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-13
- **Primary completion:** 2018-01-01
- **Final completion:** 2018-02-19
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2018-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03576521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03576521, "Evaluation of Ocoxin®-Viusid® in Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03576521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*